Skip to main content

Advertisement

SpringerLink
Log in

Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The current therapy for high-risk myelodysplastic syndrome (MDS) involves repeated cycles of the DNA demethylating agent 5-azacitidine (5-Aza), but combination treatments have been proposed to improve patient outcomes. We performed a phase Ib study to investigate the safety and tolerability of 5-Aza (75 mg/m2) combined with the histone deacetylase inhibitor panobinostat (PAN) in adult Japanese patients with MDS or chronic myelomonocytic leukemia (CMML). Eleven patients were enrolled; five received 20 mg PAN + 5-Aza and six received 30 mg PAN + 5-Aza. All patients in the 20 mg PAN cohort had MDS, while two in the 30 mg PAN cohort had MDS and three had CMML. All patients experienced ≥1 adverse event (AE) related to the study treatment, and five discontinued the study treatment because of AEs. One patient in each group exhibited dose-limiting toxicities: lung infection (PAN 20 mg + 5-Aza) and cellulitis (PAN 30 mg + 5-Aza). PAN exposure increased with ascending doses, and combination therapy did not affect PAN plasma trough concentrations. In summary, 20 or 30 mg PAN combined with 5-Aza was safe and tolerable in adult Japanese patients with CMML or MDS.

Study registration ClinicalTrials.gov Identifier: NCT01613976.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Catenacci DV, Schiller GJ. Myelodysplasic syndromes: a comprehensive review. Blood Rev. 2005;19:301–19.

    Article  CAS  PubMed  Google Scholar 

  2. Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117:7121–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28:2847–52.

    Article  PubMed  Google Scholar 

  4. Chihara D, Ito H, Katanoda K, Shibata A, Matsuda T, Sobue T, et al. Incidence of myelodysplastic syndrome in Japan. J Epidemiol. 2014;24:469–73.

    Article  PubMed  Google Scholar 

  5. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14–22.

    Article  CAS  PubMed  Google Scholar 

  6. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.

    Article  CAS  PubMed  Google Scholar 

  7. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366:1090–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895–903.

    Article  CAS  PubMed  Google Scholar 

  9. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Moe-Behrens GH, Pandolfi PP. Targeting aberrant transcriptional repression in acute myeloid leukemia. Rev Clin Exp Hematol. 2003;7:139–59.

    CAS  PubMed  Google Scholar 

  11. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103–7.

    Article  CAS  PubMed  Google Scholar 

  12. Zhu WG, Otterson GA. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents. 2003;3:187–99.

    Article  CAS  PubMed  Google Scholar 

  13. Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol. 2008;45:23–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Khot A, Dickinson M, Prince HM. Panobinostat in lymphoid and myeloid malignancies. Expert Opin Investig Drugs. 2013;22:1211–23.

    Article  CAS  PubMed  Google Scholar 

  15. Dimicoli S, Jabbour E, Borthakur G, Kadia T, Estrov Z, Yang H, et al. Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. Am J Hematol. 2012;87:127–9.

    Article  CAS  PubMed  Google Scholar 

  16. Ottmann OG, DeAngelo DJ, Garcia-Manero G, Lübbert M, Jillella A, Sekeres MA et al. Determination of a phase II dose of panobinostat in combination with 5-azacitidine in patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia. American Society of Hematology (ASH)—annual meeting 2011, Abs # 459. https://ash.confex.com/ash/2011/webprogram/Paper37915.html. Accessed 19 Jan 2016.

  17. Platzbecker U, Al-Ali HK, Gattermann N, Haase D, Janzen V, Krauter J, et al. Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients. Leukemia. 2014;28:696–8.

    Article  CAS  PubMed  Google Scholar 

  18. Luszczek W, Cheriyath V, Mekhail TM, Borden EC. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression. Mol Cancer Ther. 2010;9:2309–21.

    Article  CAS  PubMed  Google Scholar 

  19. Govindaraj C, Tan P, Walker P, Wei A, Spencer A, Plebanski M. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients. Clin Cancer Res. 2014;20:724–35.

    Article  CAS  PubMed  Google Scholar 

  20. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.

    CAS  PubMed  Google Scholar 

  21. Fukutomi A, Hatake K, Matsui K, Sakajiri S, Hirashima T, Tanii H, et al. A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors. Invest New Drugs. 2012;30:1096–106.

    Article  CAS  PubMed  Google Scholar 

  22. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med. 1998;17:1103–20.

    Article  CAS  PubMed  Google Scholar 

  23. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med. 2008;27:2420–39.

    Article  PubMed  Google Scholar 

  24. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–25.

    Article  CAS  PubMed  Google Scholar 

  25. Tan P, Wei A, Mithraprabhu S, Cummings N, Liu HB, Perugini M, et al. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J. 2014;4:e170.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496–526.

    Article  CAS  PubMed  Google Scholar 

  27. DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013;27:1628–36.

    Article  CAS  PubMed  Google Scholar 

  28. Almeida A, Fenaux P, List AF, Raza A, Platzbecker U, Santini V. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Leuk Res. 2017;52:50–7.

    Article  CAS  PubMed  Google Scholar 

  29. Prebet T, Sun Z, Ketterling RP, Zeidan A, Greenberg P, Herman J, et al. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. Br J Haematol. 2016;172:384–91.

    Article  CAS  PubMed  Google Scholar 

  30. Tan P, Soo Tiong I, Fleming S, Pomilio G, Cummings N, Droogleever M, et al. The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study. Oncotarget. 2016;. doi:10.18632/oncotarget.13699.

    Google Scholar 

  31. Schneider BJ, Shah MA, Klute K, Ocean A, Popa E, Altorki NK, et al. Phase I study of epigenetic priming with azacitidine prior to standard neoadjuvant chemotherapy for patients with resectable gastric and esophageal adenocarcinoma. Clin Cancer Res. 2017;23:2673–80.

    Article  CAS  PubMed  Google Scholar 

  32. Morita S, Oizumi S, Minami H, Kitagawa K, Komatsu Y, Fujiwara Y, et al. Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors. Investig New Drugs. 2012;30:1950–7.

    Article  CAS  Google Scholar 

  33. Tikhonova IA, Hoyle MW, Snowsill TM, Cooper C, Varley-Campbell JL, Rudin CE, et al. Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts: an evidence review group perspective of a National Institute for Health and Care Excellence single technology appraisal. Pharmacoeconomics. 2017;35:363–73.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by an independent data monitoring committee comprising three physicians: Dr. Yasushi Miyazaki of Nagasaki University, Dr. Keiya Ozawa of Jichi Medical University (currently of the Institute of Medical Science, The University of Tokyo), and Dr. Tomoki Naoe of Nagoya Medical Center. A medical expert consultancy agreement was made with Dr. Masamitsu Yanada of Fujita Health University. The authors thank J. Ludovic Croxford, Ph.D., of Edanz Medical Writing, on behalf of Springer Healthcare Communications, for providing medical writing support. This assistance was funded by Novartis Pharmaceuticals Japan.

Conflict of interest

YK received research funding from Novartis during the conduct of the study. FS, MY, FM, and TT are employees of Novartis. HM reports grants from Novartis during the conduct of the study; as well as grants from Fuji Film RI Pharma, AstraZeneca, Yakult Honsha, Berhringer Ingelheim, Astellas, Merck Serono, Sanofi, MSD, Nihon Shinyaku, Teijin Pharma, and Dainippon Sumitomo; grants and personal fees from Taisho Toyama Pharmaceutical, Novartis, Eisai, Kyowa Hakko Kirin, Chugai, Bristol Myers Squibb, Taiho, Daiichi-Sankyo, Ono, Pfizer, Eli Lilly, Takeda Pharmaceutical, and Asahi Kasei Pharma, and personal fees from Bayer, Kowa, Nippon Chemiphar, and Mochida Pharmaceutical, outside the submitted work. MO reports grants from SymBio and Celltrion and personal fees from Meiji Seika Pharma, Mundipharma, Celltrion, AstraZeneca, Takeda, Jansen Pharma, and Celgene, outside the submitted work. The remaining authors declare that they have no conflicts of interest. This industry-led study was sponsored by Novartis, who also supplied the study drugs.

Author information

Authors and Affiliations

  1. Department of Hematology, National Cancer Center Hospital, Tokyo, Japan

    Yukio Kobayashi & Wataru Munakata

  2. Department of Hematology, International University of Health and Welfare, Mita Hospital, 1-4-3 Mita, Minato-ku, Tokyo, 108-8329, Japan

    Yukio Kobayashi

  3. Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan

    Michinori Ogura & Toshiki Uchida

  4. Department of Hematology, Tokai Central Hospital, Kakamigahara, Japan

    Michinori Ogura

  5. Department of Hematology and Oncology, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan

    Masafumi Taniwaki & Tsutomu Kobayashi

  6. Oncology Department, Novartis Pharma K.K., Tokyo, Japan

    Fumika Shimada, Masataka Yonemura, Fumiko Matsuoka & Takeshi Tajima

  7. Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan

    Kimikazu Yakushijin & Hironobu Minami

Authors
  1. Yukio Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wataru Munakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michinori Ogura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshiki Uchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masafumi Taniwaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tsutomu Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fumika Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masataka Yonemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fumiko Matsuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takeshi Tajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kimikazu Yakushijin
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hironobu Minami
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yukio Kobayashi.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kobayashi, Y., Munakata, W., Ogura, M. et al. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Int J Hematol 107, 83–91 (2018). https://doi.org/10.1007/s12185-017-2327-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-017-2327-9

Keywords

Search

Navigation